Cargando…

Correlations among disability, anti-AQP4 antibody status and prognosis in the spinal cord involved patients with NMOSD

BACKGROUND: Neuromyelitis optica spectrum disorder (NMOSD) is a rare neuroinflammatory disorder of the central nervous system that typically involves the optic nerve, the spinal cord and other specific brain regions. In relapse of the disease, factors associated with clinical features and lesion sev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hsu, Jung Lung, Liao, Ming-Feng, Chang, Kuo-Hsuan, Cheng, Mei-Yun, Ro, Long-Sun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8033738/ https://www.ncbi.nlm.nih.gov/pubmed/33836682 http://dx.doi.org/10.1186/s12883-021-02171-2

Ejemplares similares

Microstructural visual system changes in AQP4-antibody–seropositive NMOSD
por: Oertel, Frederike C., et al.
Publicado: (2017)

The etiologies and prognosis associated with spinal cord infarction
por: Hsu, Jung Lung, et al.
Publicado: (2019)

AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?
por: Fragoso, Diego Cardoso, et al.
Publicado: (2023)

AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD
por: Prain, Kerri, et al.
Publicado: (2019)

Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort
por: Dauby, Solène, et al.
Publicado: (2021)

Contrasting the brain imaging features of MOG-antibody disease, with AQP4-antibody NMOSD and multiple sclerosis
por: Messina, Silvia, et al.
Publicado: (2021)

The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD
por: Berhanu, David, et al.
Publicado: (2023)

Spontaneous remission lasting more than a decade in untreated AQP4 antibody–positive NMOSD
por: Pandit, Lekha, et al.
Publicado: (2017)

Paraneoplastic NMOSD associated with EG junction adenocarcinoma expressing unprotected AQP4
por: Sudo, Atsushi, et al.
Publicado: (2018)

Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS
por: Duan, Yunyun, et al.
Publicado: (2021)

Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD
por: Finke, Carsten, et al.
Publicado: (2016)

AQP4‐IgG positive paraneoplastic NMOSD: A case report and review
por: Ding, Manqiu, et al.
Publicado: (2021)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
por: Bollo, Luca, et al.
Publicado: (2021)

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD
por: Shosha, Eslam, et al.
Publicado: (2018)

An elderly female case of AQP4 and GFAP double-positive NMOSD coexisting with ovarian teratoma
por: Yang, Jiahui, et al.
Publicado: (2023)

Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD
por: Jitprapaikulsan, Jiraporn, et al.
Publicado: (2020)

The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis
por: Roca-Fernández, A, et al.
Publicado: (2021)

Chronic Cognitive Impairment in AQP4+ NMOSD With Improvement in Cognition on Eculizumab: A Report of Two Cases
por: Saab, Georges, et al.
Publicado: (2022)

A case report on recurrent area postrema syndrome in AQP4-IgG-positive NMOSD
por: Shrestha, Ramesh, et al.
Publicado: (2022)

Different clinical phenotypes of AQP4-IgG positive NMOSD in two first degree relatives
por: Ssemmanda, Salvatore, et al.
Publicado: (2023)

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
por: Paul, Friedemann, et al.
Publicado: (2023)

Structural and Functional Alterations in Visual Pathway After Optic Neuritis in MOG Antibody Disease: A Comparative Study With AQP4 Seropositive NMOSD
por: Gao, Chenyang, et al.
Publicado: (2021)

Differential Effects of MS Therapeutics on B Cells—Implications for Their Use and Failure in AQP4-Positive NMOSD Patients
por: Traub, Jan, et al.
Publicado: (2020)

An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD
por: Carnero Contentti, Edgar, et al.
Publicado: (2021)

A comparison between spinal cord infarction and neuromyelitis optica spectrum disorders: Clinical and MRI studies
por: Hsu, Jung Lung, et al.
Publicado: (2019)

Reflections from a NMOSD case with serum AQP4-Ab negativity but CSF positivity: narrative review of how to interpret AQP4-Ab test results
por: Xue, Qun, et al.
Publicado: (2021)

Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI-visible lesions
por: Ventura, Rachel E., et al.
Publicado: (2016)

Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD
por: Dinoto, Alessandro, et al.
Publicado: (2022)

COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD
por: Yeo, Tianrong, et al.
Publicado: (2022)

Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD
por: Schroeder-Castagno, Maria, et al.
Publicado: (2022)

Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSD
por: Masuda, Hiroki, et al.
Publicado: (2023)

Postpartum Spinal Cord Infarction: A Case Report and Review of the Literature
por: Hsu, Jung-Lung, et al.
Publicado: (2022)

Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD
por: Fadda, Giulia, et al.
Publicado: (2022)

Helicobacter pylori infection may influence prevalence and disease course in myelin oligodendrocyte glycoprotein antibody associated disorder (MOGAD) similar to MS but not AQP4-IgG associated NMOSD
por: Malli, Chaithra, et al.
Publicado: (2023)

Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD
por: Akaishi, Tetsuya, et al.
Publicado: (2020)

Pretreatment with AQP4 and NKCC1 Inhibitors Concurrently Attenuated Spinal Cord Edema and Tissue Damage after Spinal Cord Injury in Rats
por: Yan, Xiaodong, et al.
Publicado: (2018)

A Comparative Analysis of Clinical and Imaging Features of Aquaporin 4 (AQP4) Antibody Positive, Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive and Double Seronegative Subtypes of Neuro Myelitis Optica Spectrum Disorder (NMOSD)
por: Gupta, Salil, et al.
Publicado: (2022)

Spinal Cord involvement in Dengue
por: Loeb, Laura, et al.
Publicado: (2021)

Adverse Events in NMOSD Therapy
por: Giglhuber, Katrin, et al.
Publicado: (2022)

Dynamic Changes in AQP4-IgG Level and Immunological Markers During Protein-A Immunoadsorption Therapy for NMOSD: A Case Report and Literature Review
por: Chen, Bo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f2r86frc1fqloef25cb26qapcb